

Global Innovator in Liver Cell-based Medicine



The Company

Promethera Biosciences' mission is to apply its proprietary liver cell-based technology to meet the needs of patients with acute and chronic liver diseases. The company is pioneering the development of cell-based therapies that provide both immunomodulatory and anti-fibrotic effects in the liver.

The company's lead clinical program is derived from a patented allogenic liver cell platform called HepaStem. Currently in a Phase II clinical trial to treat patients with Acute-on-Chronic Liver Failure (ACLF), the program has the potential to target other severe and more prevalent chronic liver diseases such as Non-Alcoholic Steatohepatitis (NASH).


Promethera has developed its technologies by using allogenic progenitor liver cells. These are isolated, purified and expanded from viable human livers unsuitable for transplantation. The process for developing these cells into a medical treatment enables the delivery of the cells to patients directly at point of care.

The company was founded in 2009 by Etienne Sokal, Promethera Biosciences' CISO and Professor of medicine at the Université Catholique de Louvain. It is located within the Walloon healthcare cluster, Biowin, in Belgium. The Walloon region is internationally known for excellence in cell therapy research. In 2016, Promethera acquired Cytonet LLC's key assets, including its US facility based in Durham, North Carolina at the heart of the Research Triangle Park (RTP), an important center for medical research and innovation in the USA. The acquisition brought a state-of-the-art production facility in the US as well as a powerful network for

sourcing US human livers from OPO's (Organ Procurement Organizations) to complement the cGMP facilities and tissue procurement centers in Belgium along with additional experienced leadership.

Since inception, Promethera has garnered the support of blue chip corporate venture funds including Boehringer Ingelheim, Shire, Mitsui and Mitsubishi and specialized venture investors such as Vesalius BioCaptial, SRIW, SMS Investments, Fund+ and the Hopp Family. Most recently the company gained capital from strategic Japanese and Korean investors, further enabling Promethera's vision of treating patients worldwide.

Disease-centrality of the liver will make it a key intervention target for novel treatments



HepaStem Development Pipeline

PLATFORM	INDICATIONS	R&D	PRE-CLINICAL	PHASE I	PHASE II	PHASE III	MAA
HepaStem	ACLF	→			Ongoing		
HepaStem	Nash/Fibrosis	→		Start of clinical development in H2, 2017			
Genetically modified HepaStem	Hemophilia A/B (FVIII/FIX)	→		Early partnering option			

At a Glance

FOUNDED

- › February 12, 2009
- › Acquisition of Cytonet's key assets April 15, 2016

MANAGEMENT

- › John Tchelingierian, PhD - Chief Executive Officer
- › Etienne Sokal, MD, PhD - Chief Innovation and Scientific Officer
- › Frank Hazevoets - Chief Financial Officer & Head of Corporate Development
- › Henrik L. Luessen, PhD - Chief Business Officer
- › Torsten Hombeck, PhD - Chief Commercial and Strategy Officer
- › Patrick Stragier - Vice President Operations
- › Nancy Veulemans - Vice President Clinical & Medical Affairs
- › Decebal Bora, Pharm. D, MPH - Vice President Regulatory Affairs

BOARD OF DIRECTORS

- › Christof Hettich (Chairman of the Board)
- › Alain Parthoens (through AQ Invest BVBA)
- › Ilka Wicke
- › Kinji Fuchikami
- › Philippe Degive (through Sparaxis SA)
- › Jean-Paul Prieels
- › Etienne Sokal, Director A
- › John Tchelingierian, Director A (through Silver Ocean Ventures SAS)


IP POSITION

- › 14 patent families and more than 280 patents and patent applications

RECENT NEWS

- › January 9, 2017: Promethera Biosciences and LifeLiver Sign Strategic Alliance to Develop Liver Disease Therapeutics in South Korea
- › November 14, 2016: Promethera Biosciences Provides Update on HepaStem NASH-Fibrosis Program with Late-Breaking Preclinical Data at 2016 AASLD Meeting
- › October 28, 2016: Promethera Biosciences Raises EUR 10 Million in a Series C- extension Financing to Advance its Broad Product Pipeline in Liver Diseases


Fully-Formed Supply Chain, Production and Product Platform



Financial Information

EUR 48.6M raised in equity since inception, not including non-dilutive support from the Walloon region of Belgium through grants and recoverable cash advances.

MAIN INVESTORS AND SHAREHOLDERS



* Essentially HNWI and private investors.

** As part of Cytonet acquisition.

PROMETHERA Biosciences SA/NV (Headoffice)

Watson & Crick Hill | Rue Granbonpré, 11
B-1435 Mont-Saint-Guibert
Tel.: +32 (0)10 39 43 00
Fax: +32 (0)10 39 43 01
info@promethera.com

PROMETHERA Biosciences LLC (US Operations)

801 Capitola Drive | Suite 8,
Durham NC27713 - U.S.A.
Tel.: +1 (919)354-1930
Fax: +1 (919)354-1931
usteam@promethera.com

John Tchelingierian, PhD, CEO

John.Tchelingierian@promethera.com

Frank Hazevoets, CFO & Head of Corporate Development

Frank.Hazevoets@promethera.com